Sharp Therapeutics Corp.
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captu… Read more
Sharp Therapeutics Corp. (SHRX) - Net Assets
Latest net assets as of : CA$- CAD
Based on the latest financial reports, Sharp Therapeutics Corp. (SHRX) has net assets worth CA$- CAD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$-) and total liabilities (CA$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Sharp Therapeutics Corp. - Net Assets Trend (None–None)
This chart illustrates how Sharp Therapeutics Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sharp Therapeutics Corp. (None–None)
The table below shows the annual net assets of Sharp Therapeutics Corp. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Sharp Therapeutics Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Sharp Therapeutics Corp. Competitors by Market Cap
The table below lists competitors of Sharp Therapeutics Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Peoples Bankshares Inc
PINK:NWPP
|
$24.89 Million |
|
Sunview Group Bhd
KLSE:0262
|
$24.90 Million |
|
GP Investments Ltd
SA:GPIV33
|
$24.90 Million |
|
6K Additive Inc
AU:6KA
|
$24.91 Million |
|
EuroDry Ltd
NASDAQ:EDRY
|
$24.88 Million |
|
Kobay Tech Bhd
KLSE:6971
|
$24.88 Million |
|
CervoMed Inc.
NASDAQ:CRVO
|
$24.88 Million |
|
First Phosphate Corp.
OTCQB:FRSPF
|
$24.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sharp Therapeutics Corp.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Sharp Therapeutics Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Sharp Therapeutics Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Sharp Therapeutics Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,651,653
- Average return on equity (ROE) among peers: 43.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sharp Therapeutics Corp. (SHRX) | CA$- | N/A | N/A | $24.89 Million |
| Innovotech Inc (IOT) | $181.51K | 415.07% | 1.90x | $4.32 Million |
| Rakovina Therapeutics Inc (RKV) | $4.30 Million | -94.74% | 0.45x | $1.14 Million |
| Thiogenesis Therapeutics Corp. (TTI) | $83.35K | -111.19% | 0.76x | $14.25 Million |
| Waverley Pharma Inc (WAVE) | $2.04 Million | -34.55% | 0.71x | $235.88K |